|
|
Dose Calculation Accuracy of Individualized Bulk Electron Density Assignment Approaches for Simulated MRI-only Planning of Thoracic Tumors |
Shuxu Zhang*#, Qingxing Zeng*, Yuliang Liao, Shengqu Lin, Guoquan Zhang, Huaiyu Lei, Ruihao Wang, Hui Yu, Quanbin Zhang, Ping Li |
Radiotherapy Center,Affiliated Cancer Hospital & Institute of Guangzhou Medical University,Guangzhou Guangdong 510095,China |
|
|
Abstract Objective This study aimed to investigate the dose calculation accuracy of individualized bulk electron density (IBED) assignment approaches for simulated magnetic resonance imaging (MRI)-only planning of thoracic tumors via the use of a 3DVH system. Methods 8 patients with thoracic cancer were included in this study. Based on standard planning CT,single-arc dynamic conformal therapy (DCT) and double-arc volumetric modulated arc therapy (VMAT) plans with a 6 MV photon beam were generated as a baseline plan (Plan-CT) for each patient. The simulated MRI-only planning (Plan-IBED) was implemented by copying the Plan-CT and forcing the electron density of each region of interest to its average value and recalculating the dose distribution. A 3DVH system was used to visualize and compare the dosimetric differences between Plan-CT and Plan-IBED,and the criteria of the 3D-Gamma pass rate were set to 1.0%/1.0 mm. Results The maximum percentage relative deviation (MPRD) of the dosimetric parameters D2,D95,D98,and Dmean of planning tumor volumes (PTVs) between Plan-CT and Plan-IBED was less than 1.3%. The MPRD of the average dose for organs at risk (OARs) was less than 1.5%. The MPRDs of the lung V5,V20,and V30 were 1.29%,3.26%,and 2.78%,respectively. Gamma analysis revealed an averaged pass rate of >95.0% for the body,as well as between 91.9% and 98.2% for OARs. Conclusion The proposed IBED assignment in simulated MRI-only treatment planning allows for dose calculation with comparable accuracy to the baseline plan and is appropriate for thoracic tumors.
|
|
|
|
|
[1] Schmidt MA,Payne GS. Radiotherapy planning using MRI[EB/OL].Phys Med Biol,2015,60:R323-R361.https://doi.org/10.1088/0031-9155/60/22/R323 [2] Nyholm T,Nyberg M,Karlsson MG,et al. Systematisation of spatial uncertainties for comparison between a MR and a CT-based radiotherapy workflow for prostate treatments[EB/OL]. Radiat Oncol,2009,54. https://doi.org/10.1186/1748-717X-4-54. [3] Kristensen BH,Laursen FJ,L-gager V,et al. Dosimetric and geometric evaluation of an open low-field magnetic resonance simulator for radiotherapy treatment planning of brain tumours[EB/OL].Radiother Oncol,2008,87(1). https://doi.org 0-910.1016/j.radonc.2008.01.014. [4] Stanescu T,Jans HS,Pervez N,et al. A study on the magnetic resonance imaging (MRI)-based radiation treatment planning of intracranial lesions[J]. Phys Med Biol,2008,53(13):3579-3593. https://doi.org/10.1088/0031-9155/53/13/013. [5] Young T,Thwaites D,Holloway L. Assessment of electron density effects on dose calculation and optimisation accuracy for nasopharynx,for MRI only treatment planning[EB/OL]. Australas Phys Eng Sci Med,2018,41(4). https://doi.org/10.1007/s13246-018-0675-2. [6] Liu Y,Lei Y,Wang T,et al. MRI-based treatment planning for liver stereotactic body radiotherapy: validation of a deep learning-based synthetic CT generation method[EB/OL].Br J Radiol,2019,92(1100):20190067. https://doi.org/10.1259/bjr.20190067. [7] Han S,Yin FF,Cai J. Evaluation of dosimetric uncertainty caused by MR geometric distortion in MRI-based liver SBRT treatment planning[EB/OL]. J Appl Clin Med Phys,2019,20(2): 43-50. https://doi.org/10.1002/acm2.12520. [8] Prior P. MRI-based IMRT planning for MR-linac: comparison between CT- and MRI-based plans for pancreatic and prostate cancers[EB/OL]. Phys Med Biol,2016,61(10):3819-3842. https://doi.org/10.1088/0031-9155/61/10/3819. [9] Vanquin L,Boydev C,Korhonen J,et al. Radiotherapy treatment planning of prostate cancer using magnetic resonance imaging alone[EB/OL].Cancer Radiother,201923(4):281-289.https://doi.org/10.1088/0031-9155/61/10/3819. [10] Nejad-Davarani SP,Sevak P,Moncion M,et al. Geometric and dosimetric impact of anatomical changes for MR-only radiation therapy for the prostate[EB/OL].J Appl Clin Med Phys,2019,20(4):10-17.https://doi.org/10.1002/acm2.12551. [11] Kemppainen R,Vaara T,Joensuu T,et al. Accuracy and precision of patient positioning for pelvic MR-only radiation therapy using digitally reconstructed radiographs[EB/OL].Phys Med Biol,2018,63(5):055009. https://doi.org/10.1088/1361-6560/aaaD21. [12] Farjam R,Tyagi N,Deasy JO,et al. Dosimetric evaluation of an atlas-based synthetic CT generation approach for MR-only radiotherapy of pelvis anatomy[EB/OL].J Appl Clin Med Phys,2019,20(1):101-109.https://doi.org/10.1002/acm2.12501. [13] Bird D,Henry AM,Sebag-Montefiore D,et al. A systematic review of the clinical implementation of pelvic magnetic resonance imaging-only planning for external beam radiation therapy[EB/OL].Int J Radiat Oncol Biol Phys,2019,105(3):479-492.https://doi.org/10.1016/j.ijrobp.2019.06.2530. [14] Karotki A,Mah K,Meijer G,et al. Comparison of bulk electron density and voxel-based electron density treatment planning[EB/OL].J Appl Clin Med Phys,2011,12(4):3522. https://doi.org/10.1120/jacmp.V12i4.3522. [15] Hsu SH,Zawisza I,O'Grady K,et al. Towards abdominal MRI-based treatment planning using population-based Hounsfield units for bulk density assignment[EB/OL].Phys Med Biol,2018,63(15):155003.https://doi.org/10.1088/1361-6560/aacfb1. [16] Choi JH,Lee D,O'Connor L,et al. Bulk anatomical density based dose calculation for patient-specific quality assurance of MRI-Only prostate radiotherapy[EB/OL].Front Oncol,2019,9:997.https://doi.org/10.3389/fonc.2019.00997. [17] Largent A,Barateau Am,Nunes JC,et al. Pseudo-CT generation for MRI-Only radiation therapy treatment planning: comparison among patch-based,atlas-based,and bulk density methods[EB/OL]. Int J Radiat Oncol Biol Phys,2019,103(2):479-490.https://doi.org/10.1016/j.ijrobp.2018.10.002. [18] Prior P,Chen X,Gore E,et al. Technical Note: Is bulk electron density assignment appropriate for MRI-only based treatment planning for lung cancer[EB/OL].Med Phys,2017,44(7):3437-3443.https://doi.org/10.1002/mp.12267 |
|
|
|